Of note, although Thomas et al. found good left-out performance for the exclusively anti-PD-1-treated NSCLC and renal cell carcinoma cohorts, performance was poor among left-out melanoma cohorts, potentially due to patients receiving monotherapy and those receiving CICB being admixed. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.